LOS ANGELES, Jan. 22, 2008—Grant Life Sciences (OTC Bulletin Board: GLIF) announced today it has received notice from the China Patent Office that Patent No. ZLO38150247—‘PEPTIDES FROM THE E2, E6 and E7 PROTEINS OF HUMAN PAPILLOMAVIRUSES 16 AND 18 FOR DETECTING AND/OR DIAGNOSING CERVICAL AND OTHER CANCERS’—has issued to the Company.
In addition, the Company also announced that it has received notice from the U.S. Patent & Trademark Office that Patent No. 7,316,908—‘PEPTIDES FROM THE E2 PROTEINS OF HUMAN PAPILLOMAVIRUSES 16 AND 18 FOR DETECTING AND/OR DIAGNOSING CERVICAL AND OTHER HUMAN PAPILLOMAVIRUS-ASSOCIATED CANCERS—has issued to the Company.
“While we are excited by both of these events, in particular this action by the Chinese government clears a path for us to move forward confidently as we seek a China-based development-and-commercialization partner for our serum-based test for cervical cancer in the largest market in the world,” said Hun-Chi Lin, Ph.D., Grant’s President and Chief Scientist, “and we fully expect that this Chinese patent will help us realize our goal of a Chinese partner.”
About Grant Life Sciences Inc.
Grant Life Sciences Inc., a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women’s health, infectious diseases, and cancers.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.